Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

674
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
674
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

290
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
290
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

191
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
191
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

11
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
11
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

212
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
212
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

332
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
332

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Optimized flow cytometry assay for functional characterization of variants of uncertain significance in familial hypercholesterolemia.

Atherosclerosis·2026
Same author

Managing remnant cholesterol: role of fenofibrate-statin therapy in reducing triglyceride-rich lipoproteins.

Frontiers in cardiovascular medicine·2026
Same author

Lipid clinics worldwide: harmonization and guidance on how to optimally organize and fund. European Atherosclerosis Society consensus statement across 55 countries and more than 500 lipid clinics.

Atherosclerosis·2026
Same author

Pathogenic interplay between markedly elevated plasma lipoprotein(a) levels and prothrombotic mechanisms: a case report.

Frontiers in cardiovascular medicine·2026
Same author

Focus on lipoprotein(a).

European heart journal supplements : journal of the European Society of Cardiology·2026
Same author

Lipid management in type 2 diabetes and non-HDL-cholesterol: target all atherogenic lipoproteins.

Cardiovascular diabetology·2026

Related Experiment Video

Updated: Jul 11, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

Lipid-lowering in diabetes: An update.

Alan Chait1, Robert H Eckel2, Michal Vrablik3

  • 1Division of Metabolism, Endocrinology and Nutrition, Department of Medicine, University of Washington, WA, USA.

Atherosclerosis
|November 9, 2023
PubMed
Summary
This summary is machine-generated.

People with diabetes experience accelerated atherosclerotic cardiovascular disease (ASCVD). Combination therapies, like statin plus ezetimibe, are recommended for managing dyslipidemia and preventing ASCVD events.

More Related Videos

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.0K
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.8K

Related Experiment Videos

Last Updated: Jul 11, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.0K
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.8K

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetes mellitus accelerates atherosclerotic cardiovascular disease (ASCVD) through mechanisms like dyslipidemia, hyperglycemia, oxidative stress, and inflammation.
  • Type 1 diabetes presents unique factors contributing to accelerated atherosclerosis.
  • Clinical guidelines exist for screening, risk assessment, and treatment of ASCVD in diabetic patients.

Purpose of the Study:

  • To review current strategies for preventing ASCVD in individuals with diabetes.
  • To discuss the role of lipid management in mitigating ASCVD risk.
  • To evaluate the efficacy and rationale for various therapeutic interventions.

Main Methods:

  • Review of existing clinical guidelines and therapeutic approaches for ASCVD prevention in diabetes.
  • Analysis of the benefits of statin therapy and the need for supplemental treatments.
  • Evaluation of emerging therapies targeting lipoprotein metabolism.

Main Results:

  • Statin therapy significantly reduces cardiovascular disease (CVD) events in diabetic patients.
  • Many patients require additional therapies (ezetimibe, bempedoic acid, PCSK9 inhibitors) to achieve recommended low-density lipoprotein (LDL) goals.
  • Combination therapy, particularly statin plus ezetimibe, is a rational initial treatment strategy.
  • Icosapent-ethyl shows benefit, potentially through non-triglyceride-lowering mechanisms.
  • Novel agents like apoC-III and ANGPTL3 inhibitors demonstrate promise for further lipoprotein reduction.

Conclusions:

  • Aggressive lipid management is crucial for preventing ASCVD in diabetes.
  • Combination therapies are often necessary to achieve LDL targets.
  • Emerging treatments offer future potential for enhanced ASCVD risk reduction in this population.